Industry News


Kura Oncology Starts Dosing Patients in Phase II CMML Study

2017-01-18 zacks
Kura Oncology, Inc. (KURA - Free Report) announced the dosing of the first patient in a phase II study on its farnesyl transferase inhibitor, tipifarnib, for the treatment of chronic myelomonocytic leukemia (CMML).

Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit

2017-01-18 zacks
Biogen Inc. (BIIB - Free Report) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP - Free Report) with respect to an ongoing patent dispute for Biogen’s best-selling multiple sclerosis (MS) drug, Tecfidera.

Becton, Dickinson Commercially Launches Precise WTA Kits

2017-01-18 zacks
Leading global medical technology company Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis (WTA) kits commercial available. These kits give an easier way of identifying and quantifying genetic information in individual cells for genomics-based research. Over the past one year, BD returned almost 21.

Benitec Stock Up on Orphan Drug Status for BB-301 in EU

2017-01-18 zacks
Shares of Benitec Biopharma Limited surged 62.2% after the company announced that its proposed candidate, BB-301, has received Orphan Drug Designation in the EU for the treatment of patients with ocularpharyngeal muscular dystrophy (OPMD). A look at Benitec’s price movement in the past one year shows that the company has underperformed the Medical-Biomedical/Genetics industry. Specifically, the stock declined 23.

AstraZeneca Offers Update on Immuno-Oncology Program

2017-01-18 zacks
AstraZeneca plc (AZN - Free Report) provided an update on its late-stage immuno-oncology program for first-line non-small cell lung cancer (NSCLC), including amendments of the MYSTIC study, expansion of the NEPTUNE study and initiation of the new PEARL study.

AtriCure - Management Needs To Find A Cure For Continued Losses

2017-01-18 seekingalpha
AtriCure is a great growth story but losses, and the resultant dilution, limit growth for investors.

IRADIMED CORPORATION announces FY2017 and Q1 guidance

2017-01-18 seekingalpha
For 2017, Company expects revenue of $23.9M -$24.3M, GAAP EPS of $0.07 - $0.08 and non-GAAP EPS of $0.14 - $0.18.

Premarket analyst action - healthcare

2017-01-18 seekingalpha
Deutsche Bank has been busy. Initiations: Agilent (NYSE:A) Buy rating and $54 price target; Bio-Rad (NYSE:BIO) Hold rating and $195 price target; Bio-Techne (NASDAQ:TECH) Buy rating and $115 price target; Bruker (NASDAQ:BRKR) Hold rating and $24 price target; Genomic Health (NASDAQ:GHDX) Hold rating and $31 price target; Hologic (NASDAQ:HOLX) Buy rating and $48 price target; Illumina (NASDAQ:ILMN) Hold rating and $160 price target; LabCorp (NYSE:LH) Buy with $170 price target; Luminex (NASDAQ:LMNX) Sell rating and $18 price target; Myriad Genetics (NASDAQ:MYGN) Sell rating and $15 price target; PerkinElmer (NYSE:PKI) Hold rating and $55 price target; Quest Diagnostics (NYSE:DGX) Buy rating and $108 price target; Thermo Fisher (NYSE:TMO) Buy Rating and $163 price target.

Bull of the Day: B&G Foods (BGS)

2017-01-18 zacks
B&G Foods (BGS) is a food products company with a huge portfolio of well-known brands. They manufacture and market processed and packaged foods across the United States and Canada.

Harwood Feffer LLP Announces Investigation of Derma Sciences Inc.

2017-01-17 prnewswire
NEW YORK, Jan. 17, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Derma Sciences Inc. ("Derma" or the "Company") (NASDAQ: DSCI) concerning the proposed acquisition of the Company by Integra LifeSciences Holdings Corporation ("Integra").

Lifshitz & Miller Law Firm Announces Investigation of Calamos Asset Management, Inc., CDI Corp., comScore, Inc., Earthstone Energy, Inc., Heritage Oaks Bancorp, Insmed Incorporated, OCI Partners LP and Vascular Solutions, Inc.

2017-01-17 prnewswire
Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed sale of CLMS to an entity formed by CLMS's Chairman and CEO for $8.25 in cash per share. 

Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017

2017-01-17 zacks
We issued an updated research report on Biogen Inc. (BIIB - Free Report) on Jan 16. The leading biotechnological company holds a strong position in the multiple sclerosis (MS) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy.

Dermal Filler Market: Clinics and Hospital Pharmacies Most Popular Distribution Segment: North America and Europe Industry Analysis and Opportunity Assessment, 2016-2026

2017-01-17 prnewswire
NEW YORK, Jan. 17, 2017 /PRNewswire/ -- Dermal fillers are implants classified as medical devices by US FDA and are used in aesthetic procedures such as anti-aging, aesthetic corrections and facial contours. Dermal fillers are used for anti-aging practices for removal of wrinkles and folds in nasolabila, volume loss in chin and cheek area, lines and wrinkles around eye. Dermal fillers considered in the report include absorbable dermal fillers and non-absorbable dermal fillers depending upon their bio-degradability after injecting inside the dermal area below skin.

Infection Control (Disinfection & Sterilization) Global Market - Forecast to 2022

2017-01-17 prnewswire
NEW YORK, Jan. 17, 2017 /PRNewswire/ -- Healthcare associated infections which mainly includes hospital or community acquired infections are persisting factor in each and every healthcare system. Increase in occurrence of hospital acquired infections and advancements in sterilization and disinfection technologies are making the infection prevention and control market promising. For reduction of hospital acquired infections, infection prevention control organizations are applying epidemiologic and scientific principles and statistic analysis.

3 Medical Device Stocks Likely to Beat Earnings Estimates

2017-01-17 zacks
As we are fast approaching the day when the new president will disclose his final plan to replace the Affordable Care Act and propose his "insurance for everybody"  strategy, the nation is clearly divided into ‘we need’ and ‘don’t need’ camps for the existing healthcare policy. Amid all this, one thing is pretty clear. The republican win has ensured a great victory for the entire medical device industry as the likely revocation of the 2.

3M Is A Second Rate Industrial Trading For A Premium Price

2017-01-17 seekingalpha
Estimates are probably still too high for 2017 and Q4 looks to be very weak; I'm still short.